The two roles a preclinical study cannot run without

What these rules govern, and what falls outside them

Good laboratory practice regulations apply to nonclinical laboratory studies that support, or are intended to support, applications for research or marketing permits for products the agency regulates. The scope section states the point of them directly: compliance is intended to assure the quality and integrity of the safety data filed with the agency.

The definition of a nonclinical laboratory study is narrow and worth reading twice. It means in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety. It does not include studies using human subjects, clinical studies or field trials in animals. And it does not include basic exploratory studies carried out to determine whether a test article has any potential utility, or to determine physical or chemical characteristics of a test article.

That last exclusion is the one that decides most arguments. A screening experiment asking whether a molecule does anything interesting is not a nonclinical laboratory study under this part. A prospective safety study intended to support a regulatory filing is.

The applications the studies feed into are listed by name, and the list includes an investigational new drug application, a new drug application, and an application for a biologics licence. The rule also reaches outward: where a sponsor uses a consulting laboratory, contractor or grantee to perform an analysis or other service for such a study, it must notify them that the service is part of a study that has to be conducted in compliance.

The study director is the single point of study control

The rule names one individual per study and gives that person an unusually complete set of responsibilities. A scientist or other professional of appropriate education, training and experience is identified as the study director. That person has overall responsibility for the technical conduct of the study, and for the interpretation, analysis, documentation and reporting of results, and — in the rule's own phrase — represents the single point of study control.

Six specific assurances sit under that. The study director must assure that the protocol, including any change, is approved as the protocol section requires and is followed. That all experimental data, including observations of unanticipated responses of the test system, are accurately recorded and verified. That unforeseen circumstances which may affect the quality and integrity of the study are noted when they occur, and corrective action taken and documented. That test systems are as specified in the protocol. That all applicable good laboratory practice regulations are followed. And that all raw data, documentation, protocols, specimens and final reports are transferred to the archives during or at the close of the study.

This is why two dates in the definitions section are defined by a signature rather than by an event. Study initiation date means the date the protocol is signed by the study director. Study completion date means the date the final report is signed by the study director. A study begins and ends when one identified person puts their name to a document.

The role cannot be left vacant. Testing facility management must designate a study director before the study is initiated, and must replace the study director promptly if it becomes necessary to do so during the study.

The quality assurance unit is defined by what it is not allowed to do

The second role is structural rather than scientific. A testing facility must have a quality assurance unit responsible for monitoring each study, to assure management that the facilities, equipment, personnel, methods, practices, records and controls conform to the regulations.

The definition of that unit contains an exclusion: it means any person or organisational element, except the study director, designated by management to perform quality assurance duties. The operating requirement goes further. For any given study, the quality assurance unit must be entirely separate from and independent of the personnel engaged in the direction and conduct of that study.

Seven duties are listed. Maintain a master schedule sheet of all nonclinical laboratory studies at the facility, indexed by test article, showing the test system, the nature of the study, the date it was initiated, its current status, the identity of the sponsor and the name of the study director. Maintain copies of all protocols for studies the unit is responsible for. Inspect each study at intervals adequate to assure its integrity, keeping written and properly signed records of each inspection showing the date, the study, the phase or segment inspected, the person inspecting, findings and problems, action recommended and taken, and any scheduled reinspection date. Periodically submit written status reports on each study to management and the study director, noting problems and corrective actions.

The remaining three are the ones that reach the published record. Determine that no deviations from approved protocols or standard operating procedures were made without proper authorisation and documentation. Review the final study report to assure that it accurately describes the methods and standard operating procedures, and that the reported results accurately reflect the raw data. And prepare and sign a statement, to be included with the final report, specifying the dates inspections were made and the dates findings were reported to management and to the study director.

One duty carries a deadline written as an instruction rather than a number. Any problems found during an inspection which are likely to affect study integrity must be brought to the attention of the study director and management immediately.

What management owes, and what every person in the room owes

Testing facility management has its own seven-item list, and it is a useful checklist for anyone trying to understand where a preclinical study can go wrong before a single animal is dosed.

Management must designate a study director before initiation and replace them promptly if needed. Assure that there is a quality assurance unit. Assure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability and uniformity, as applicable. Assure that personnel, resources, facilities, equipment, materials and methodologies are available as scheduled. Assure that personnel clearly understand the functions they are to perform. And assure that any deviations reported by the quality assurance unit are communicated to the study director and that corrective actions are taken and documented.

The personnel requirements underneath are more concrete than the phrase suggests. Each individual engaged in or responsible for supervising a study must have education, training and experience, or a combination, enabling them to perform their assigned functions — and the facility must maintain a current summary of training and experience and a job description for each such individual. Those summaries may be retained with other employment records for the same period as the study records.

There must be a sufficient number of personnel for the timely and proper conduct of the study according to the protocol. Personnel must take necessary personal sanitation and health precautions designed to avoid contamination of test and control articles and test systems, and must wear clothing appropriate to their duties, changed as often as necessary to prevent microbiological, radiological or chemical contamination.

One requirement is easy to skim past and is genuinely unusual. Any individual found at any time to have an illness that may adversely affect the quality and integrity of a study must be excluded from direct contact with test systems, test and control articles, and any other operation or function that may adversely affect the study, until the condition is corrected. All personnel must be instructed to report to their immediate supervisors any health or medical conditions that may reasonably be considered to have an adverse effect on a study.

The one record the regulator cannot copy

The inspection section grants the agency broad access: a testing facility must permit an authorised employee, at reasonable times and in a reasonable manner, to inspect the facility and to inspect — and in the case of records also to copy — all records and specimens required to be maintained regarding studies within the part's scope.

Then it carves out an exception, and the exception is narrow and deliberate. The records inspection and copying requirements do not apply to quality assurance unit records of findings and problems, or to actions recommended and taken.

The reason is structural rather than protective. A quality assurance unit that knew every internal finding would be copied by a regulator would have an incentive to write less. The rule instead keeps the substance of the unit's findings internal while making its existence and discipline verifiable: a designated agency representative has access to the written procedures established for inspections, and may request management to certify that inspections are being implemented, performed, documented and followed up in accordance with the rule. The master schedule sheet, protocol copies and inspection records are maintained by the unit as an easily accessible system of records.

A refusal to allow inspection at all carries a plain consequence. The agency will not consider a nonclinical laboratory study in support of an application for a research or marketing permit if the testing facility refuses to permit inspection — while noting that this does not relieve the applicant of any other obligation to submit the study's results.

For a reader assessing a preclinical result cited on a product page, none of this is a stamp to look for on a paper. Published animal work is generally not accompanied by a good laboratory practice statement, and papers rarely say who the study director was or whether an independent quality unit reviewed the report against the raw data. The value of knowing the structure is that it names, precisely, the things a published methods section usually leaves out.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 58.1 and 58.3 — Scope and Definitions, read in full for the statement that compliance assures the quality and integrity of safety data, the definition of a nonclinical laboratory study and its exclusion of basic exploratory work, the definitions of quality assurance unit and study director, and the definitions of study initiation date and study completion date by signature — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
2. 21 CFR 58.15 — Inspection of a testing facility, read in full for the agency's inspection and copying right, the express exclusion of quality assurance unit records of findings, problems and actions recommended and taken, and the consequence that a study will not be considered if inspection is refused — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
3. 21 CFR 58.29 — Personnel, read in full for the education, training and experience requirement, the current summary of training and job description for each individual, the sufficient-number requirement, the sanitation and clothing requirements, and the illness exclusion and self-reporting duty — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
4. 21 CFR 58.31 — Testing facility management, read in full for the seven duties including designating a study director before initiation, prompt replacement, assuring a quality assurance unit exists, and assuring test and control articles were tested for identity, strength, purity, stability and uniformity — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
5. 21 CFR 58.33 — Study director, read in full for the single point of study control phrasing and the six assurances covering protocol approval and adherence, accurate recording and verification of experimental data, documentation of unforeseen circumstances, test systems as specified, compliance with the part, and transfer of all materials to the archives — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026
6. 21 CFR 58.35 — Quality assurance unit, read in full for the independence requirement, the seven listed duties including the master schedule sheet contents and the signed statement included with the final report, the immediate-notification duty for problems likely to affect study integrity, and the agency representative's access to written inspection procedures and certification request — Electronic Code of Federal Regulations, National Archives and Records Administration, September 2026